Crescent Biopharma Cash Flow Statement
NASDAQ: CBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.91+0.79 (+5.59%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Crescent Biopharma free cash flow
In fiscal 2025, Crescent Biopharma generated -$71.5 million of operating cash flow and spent $919,000 on capital expenditures. That left free cash flow of -$72.5 million, a free-cash-flow margin of -668.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Crescent Biopharma cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -153.94M | -37.88M | -36.90M | -46.69M | -63.43M | -51.03M | -57.89M | -48.27M | -33.28M | -31.81M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 84.00K | 35.17K | 153.30K | 207.15K | 264.60K | 270.75K | 279.23K | 275.12K | 263.54K | 190.54K |
| Stock-Based Compensation | 13.30M | 4.70M | 3.52M | 3.86M | 6.09M | 6.90M | 6.22M | 4.59M | 3.76M | 2.96M |
| Change in Working Capital | -13.68M | 1.30M | -1.02M | -5.17M | -266.64K | 4.74M | -577.19K | 1.51M | -1.03M | -1.54M |
| Operating Cash Flow | -71.53M | -31.10M | -34.88M | -46.46M | -57.49M | -39.24M | -51.98M | -43.33M | -29.77M | -29.73M |
| Capital Expenditures | -919.00K | -9.97K | -21.39K | -84.19K | -14.94K | -68.51K | -144.93K | -125.62K | -294.11K | -704.20K |
| Investing Cash Flow | -72.92M | 20.03K | -21.39K | -84.19K | -14.94K | -68.51K | -144.93K | -125.62K | -294.11K | -704.20K |
| Debt Issued | 0 | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | 322.98M | 5.40K | 28.82M | 4.16M | 10.72M | 18.14M | 412.91K | 129.45M | 113.95M | 23.67M |
| Net Change in Cash | 178.53M | -31.07M | -6.08M | -42.38M | -46.78M | -21.17M | -51.72M | 85.99M | 83.88M | -6.76M |
| Free Cash Flow | -72.45M | -31.11M | -34.90M | -46.54M | -57.50M | -39.31M | -52.13M | -43.46M | -30.06M | -30.44M |
This table shows 10 annual periods of Crescent Biopharma's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CBIO's reporting calendar. What is a cash flow statement?